ATE433446T1 - Substituierte imidazole mit krebsremmender und cytokininhibierender wirkung - Google Patents

Substituierte imidazole mit krebsremmender und cytokininhibierender wirkung

Info

Publication number
ATE433446T1
ATE433446T1 AT96937654T AT96937654T ATE433446T1 AT E433446 T1 ATE433446 T1 AT E433446T1 AT 96937654 T AT96937654 T AT 96937654T AT 96937654 T AT96937654 T AT 96937654T AT E433446 T1 ATE433446 T1 AT E433446T1
Authority
AT
Austria
Prior art keywords
cancer
cytokin
substituted imidazoles
inhibiting effects
atom
Prior art date
Application number
AT96937654T
Other languages
English (en)
Inventor
Harold Selnick
David Claremon
Nigel Liverton
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602907.9A external-priority patent/GB9602907D0/en
Priority claimed from GBGB9602975.6A external-priority patent/GB9602975D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE433446T1 publication Critical patent/ATE433446T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT96937654T 1995-10-06 1996-10-02 Substituierte imidazole mit krebsremmender und cytokininhibierender wirkung ATE433446T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US505995P 1995-10-06 1995-10-06
US506395P 1995-10-06 1995-10-06
GBGB9602907.9A GB9602907D0 (en) 1996-02-13 1996-02-13 Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GBGB9602975.6A GB9602975D0 (en) 1996-02-13 1996-02-13 Acyl heterocylcic substituted imidazoles having anti-cancer and cytokine inhibitory activity
PCT/US1996/015880 WO1997012876A1 (en) 1995-10-06 1996-10-02 Substituted imidazoles having anti-cancer and cytokine inhibitory activity

Publications (1)

Publication Number Publication Date
ATE433446T1 true ATE433446T1 (de) 2009-06-15

Family

ID=27451400

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96937654T ATE433446T1 (de) 1995-10-06 1996-10-02 Substituierte imidazole mit krebsremmender und cytokininhibierender wirkung

Country Status (17)

Country Link
EP (1) EP0854870B1 (de)
JP (1) JP3382951B2 (de)
KR (1) KR19990064117A (de)
CN (1) CN1117082C (de)
AT (1) ATE433446T1 (de)
AU (1) AU702146B2 (de)
CA (1) CA2234066C (de)
CZ (1) CZ292707B6 (de)
DE (1) DE69637948D1 (de)
EA (1) EA001203B1 (de)
EE (1) EE03681B1 (de)
IL (1) IL123950A (de)
NO (1) NO981528L (de)
NZ (1) NZ321738A (de)
PL (1) PL184819B1 (de)
SK (1) SK282496B6 (de)
WO (1) WO1997012876A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
JP2000504023A (ja) * 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド 癌治療方法
HUP0001140A3 (en) * 1996-12-05 2002-05-28 Amgen Inc Thousand Oaks Substituted pyrimidinone and pyridone compounds and methods of use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
AR038955A1 (es) * 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
EP1314731A3 (de) * 1996-12-05 2004-01-02 Amgen Inc. Substituierte Pyrimidinverbindungen und ihre Verwendung
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
EP0988301B1 (de) 1997-06-12 2006-08-09 Aventis Pharma Limited Imidazolyl-cyclische acetale
WO1998056377A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
WO1998057966A1 (en) 1997-06-19 1998-12-23 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
WO1999001452A1 (en) 1997-07-02 1999-01-14 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
WO1999017776A1 (en) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Novel cycloalkenyl substituted compounds
US6335340B1 (en) 1997-12-19 2002-01-01 Smithkline Beecham Corporation compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
NZ526958A (en) 1998-05-22 2004-12-24 Smithkline Beecham Corp Novel 2-alkyl substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
CA2346665A1 (en) 1998-10-07 2000-04-13 Smithkline Beecham Corporation Novel treatment for stroke management
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
PL351148A1 (en) 1999-04-23 2003-03-24 Takeda Chemical Industries Ltd 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
WO2001010865A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. p38MAP KINASE INHIBITORS
JP2003528043A (ja) 1999-11-23 2003-09-24 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４‐ジヒドロ−（１Ｈ）キナゾリン−２−オン化合物
WO2001038314A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0005357D0 (en) * 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
DE60103136T2 (de) 2000-03-06 2004-10-28 Smithkline Beecham Plc, Brentford Imidazolderivate als Raf-Kinase Inhibitoren
EP1268474A2 (de) 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituierte 1,3-thiazol-verbindungen, ihre herstellung und verwendung
JP2004516237A (ja) 2000-06-21 2004-06-03 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー ケモカイン受容体活性調節剤としてのピペリジンアミド類
FR2818978B1 (fr) * 2000-12-28 2003-02-28 Sod Conseils Rech Applic Modulateurs de canaux sodiques derives de 2-piperidylimidazoles
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
WO2004004725A2 (en) 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
MXPA05009459A (es) 2003-03-03 2006-05-17 Array Biopharma Inc Inhibidores de p38 y sus metodos de uso.
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7250434B2 (en) 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
AU2007210073B2 (en) 2006-01-31 2011-10-06 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
BRPI0908906A2 (pt) * 2008-03-21 2019-09-24 Novartis Ag compostos heterocíclicos e usos dos mesmos
US12552768B2 (en) 2021-03-04 2026-02-17 Industry-University Cooperation Foundation Pyridinylpyrazole derivative or pharmaceutically acceptable salt thereof and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9300141A (es) * 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
AU7629594A (en) * 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease

Also Published As

Publication number Publication date
EE03681B1 (et) 2002-04-15
CN1203590A (zh) 1998-12-30
EP0854870A1 (de) 1998-07-29
NZ321738A (en) 1999-11-29
NO981528D0 (no) 1998-04-03
IL123950A (en) 2001-04-30
PL184819B1 (pl) 2002-12-31
CN1117082C (zh) 2003-08-06
JPH11514353A (ja) 1999-12-07
JP3382951B2 (ja) 2003-03-04
CA2234066C (en) 2005-12-13
EE9800083A (et) 1998-10-15
SK282496B6 (sk) 2002-02-05
NO981528L (no) 1998-06-05
CA2234066A1 (en) 1997-04-10
KR19990064117A (ko) 1999-07-26
EA199800268A1 (ru) 1998-12-24
EP0854870B1 (de) 2009-06-10
EP0854870A4 (de) 1999-01-07
EA001203B1 (ru) 2000-12-25
AU7514396A (en) 1997-04-28
AU702146B2 (en) 1999-02-11
WO1997012876A1 (en) 1997-04-10
SK43598A3 (en) 1998-11-04
DE69637948D1 (de) 2009-07-23
CZ292707B6 (cs) 2003-11-12
PL326025A1 (en) 1998-08-17
CZ104398A3 (cs) 1998-07-15

Similar Documents

Publication Publication Date Title
EP0854870A4 (de) Substituierte imidazole mit krebsremmender und cytokininhibierender wirkung
DE69733135D1 (de) Substituierte imidazole mit cytokinin-inhibirender wirkung
NO985864L (no) Nye anti-virale forbindelser
DE69838172D1 (de) Oxindolylchinazolinderivate als angiogenesehemmer
DE69825603D1 (de) 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2
KR910016330A (ko) 엘라스타제 억제제로서 벤즈이소티아졸리논-1-디옥사이드 유도체 및 그 조성물과 용도
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
ATE182780T1 (de) Antiseborrhoische zusammensetzung
PT1080081E (pt) Derivados do benzofuraxano e a sua utilizacao no tratamento da angina de peito
AR005120A1 (es) Derivados 4-(1h-benzimidazol-2-il) [1,4]diazepanos substituidos utiles para el tratamiento de enfermedades alergicas, composicion farmaceutica y usos en la fabricacion de medicamentos.
ATE169217T1 (de) Verwendung von furanonderivaten zur vorbeugung oder behandlung von autoimmunkrankheiten
DK0745083T3 (da) 2-Heteroaryl-5, 11-dihydro-6H-dipyrido[3, 2-b:2', 3'-e][1, 4]diazepiner og deres anvendelse til forebyggelse eller behandli
BR9307331A (pt) Compostos neuroprotetores 3,4-dihidro-2(1ho-quinolona
ATE24911T1 (de) Pyrido(3',4':4,5)furo(3,2-g)coumarine oder pyrido(3,4-h)psoralene, herstellung, verwendung in der kosmetologie und als arzneimittel und diese enthaltende zubereitungen.
MX9802732A (es) Imidazolas substituidas que tienen actividad anticancer e inhibidora de citocina.
DK601583A (da) Carbamyloxybenzhydrolderivater
KR950008514A (ko) 과산화지질이 관여하는 질환의 치료제 또는 예방제
CA2257200A1 (en) Substituted imidazoles having cytokine inhibitory activity
DE69307414D1 (de) Dipeptidderivate und diese als aktive Bestandteile enthaltendes prophylaktisches oder therapeutisches Mittel gegen Knochenkrankheiten
ATE124398T1 (de) 1,3,4-trisubstituierte piperidin-derivate, ihre herstellung und verwendung.
KR950702830A (ko) 치환된 아자스피란을 사용한 건선 치료 방법(methods of treating psoriasis employing substituted azaspiranes)
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
KR950005921A (ko) 상처 치료를 촉진시키기 위한 조성물
ECSP951499A (es) Compuestos ariltios

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties